Pharma sector posts 5% YoY earnings growth in 3QCY26/1QFY27 despite Afghan export disruption
Pharma Sector Review - 3QCY26/1QFY27
Research by: JS Global | Date: November 18, 2026
Report Overview
JS Global has released a comprehensive review of the Pakistani pharmaceutical sector for 3QCY26/1QFY27, covering 9 listed companies that represent approximately 93% of the sector's market capitalization on the Pakistan Stock Exchange (PSX). During the quarter, the sample companies posted a 1% YoY revenue decline but achieved a 5% YoY growth in cumulative earnings.
Sector Financial & Business Trends
While industry data showed +12% YoY / +8% QoQ revenue growth, the listed sample reflected -1% YoY / +6.3% QoQ growth due to higher trade discounts and the suspension of exports to Afghanistan. Exports via land have been disrupted since Oct-2025 and via air since Apr-2026. However, strong gross margins—improving to an industry average of 45% (+2.4ppts QoQ / +3ppts YoY)—supported overall sector profitability through cost optimization and pricing adjustments.
Company-Wise Valuations & Financial Highlights
The pharma sector has underperformed the KSE-100 index with a 15% drop CYTD, bringing the sector trailing P/E down to 11.4x compared to its 12-month average of 18.2x. Below is a summary table of key financial metrics for sample companies:
| Company | Code | Market Cap (Rs mn) | Sales Growth | Gross Margin | Trailing P/E (x) |
|---|---|---|---|---|---|
| AGP* | AGP | 43,162 | -4% | 61% | 12.17 |
| GlaxoSmithKline | GLAXO | 106,107 | 12% | 39% | 9.66 |
| Abbot Labs | ABOT | 98,458 | 4% | 38% | 10.60 |
| Ferozsons Labs* | FEROZ | 15,711 | 24% | 45% | 15.08 |
| The Searle Company | SEARL | 46,552 | 18% | 53% | 11.59 |
Key Catalysts
- Recovery in demand heading into the winter season with higher incidences of viral diseases.
- Potential reopening of the Afghan border or humanitarian drug export allowances via international donor agencies.
- Eventual drug price adjustments as demand picks up.
- Rising demand for new products and affordable local substitutes for global brands.
Investor Takeaway
JS Global views the long-term pharma demand outlook as intact, supported by Pakistan's favorable demographics. Recent underperformance has made sector valuations attractive, presenting opportunities for medium-to-long-term investors.